Evaxion A/S (NASDAQ:EVAX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Evaxion A/S (NASDAQ:EVAX) in a research note published on Monday morning,Benzinga reports. They currently have a $16.00 price target on the stock.

Several other brokerages have also issued reports on EVAX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 14th. Wall Street Zen raised Evaxion A/S to a “hold” rating in a research note on Friday, June 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Evaxion A/S presently has a consensus rating of “Hold” and an average price target of $13.50.

Evaxion A/S Price Performance

Evaxion A/S stock opened at $7.09 on Monday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 3.42 and a current ratio of 3.42. The firm has a market cap of $9.93 million, a P/E ratio of -5.37 and a beta of 0.23. The business’s fifty day moving average is $4.11 and its two-hundred day moving average is $2.85. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $15.50.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.26). The business had revenue of $0.04 million during the quarter. Equities research analysts forecast that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evaxion A/S

A hedge fund recently raised its stake in Evaxion A/S stock. Merck & Co. Inc. raised its stake in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) by 123.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,214,126 shares of the company’s stock after buying an additional 671,847 shares during the quarter. Evaxion A/S accounts for about 1.4% of Merck & Co. Inc.’s portfolio, making the stock its 6th largest position. Merck & Co. Inc. owned approximately 86.54% of Evaxion A/S worth $2,246,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.